X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
single-administration pegfilgrastim (239) 239
humans (181) 181
oncology (156) 156
daily filgrastim (154) 154
filgrastim (142) 142
index medicus (129) 129
colony-stimulating factor (120) 120
chemotherapy (119) 119
febrile neutropenia (110) 110
female (109) 109
polyethylene glycols (106) 106
neutropenia (100) 100
granulocyte colony-stimulating factor - therapeutic use (99) 99
breast-cancer (97) 97
multicenter (97) 97
pegfilgrastim (95) 95
middle aged (90) 90
recombinant proteins (84) 84
neutropenia - chemically induced (80) 80
aged (79) 79
male (76) 76
adult (75) 75
granulocyte colony-stimulating factor (75) 75
double-blind (73) 73
cancer (69) 69
neutropenia - prevention & control (63) 63
non-hodgkins-lymphoma (63) 63
neutropenia - drug therapy (57) 57
granulocyte colony-stimulating factor - administration & dosage (56) 56
antineoplastic agents - adverse effects (55) 55
g-csf (55) 55
phase-iii (53) 53
treatment outcome (50) 50
pharmacology & pharmacy (47) 47
breast neoplasms - drug therapy (46) 46
neoplasms - drug therapy (44) 44
breast cancer (43) 43
antineoplastic combined chemotherapy protocols - adverse effects (41) 41
cell lung-cancer (40) 40
hematology (39) 39
cycle (37) 37
chemotherapy-induced neutropenia (34) 34
granulocyte colony-stimulating factor - adverse effects (34) 34
induced febrile neutropenia (34) 34
health care sciences & services (32) 32
antineoplastic combined chemotherapy protocols - administration & dosage (30) 30
recombinant proteins - therapeutic use (30) 30
drug administration schedule (29) 29
drug therapy (29) 29
medicine & public health (28) 28
adjuvant chemotherapy (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
retrospective studies (27) 27
dose-intensity (26) 26
dose-response relationship, drug (26) 26
growth-factors (26) 26
research (26) 26
care and treatment (25) 25
elderly-patients (24) 24
patients receiving chemotherapy (24) 24
young adult (24) 24
aged, 80 and over (23) 23
risk (23) 23
colony-stimulating factors (22) 22
risk factors (22) 22
nursing (21) 21
antineoplastic agents - therapeutic use (20) 20
doxorubicin - administration & dosage (20) 20
lymphoma, non-hodgkin - drug therapy (20) 20
recombinant proteins - administration & dosage (20) 20
open-label (19) 19
stage-ii (19) 19
cyclophosphamide - administration & dosage (18) 18
granulocyte colony-stimulating factor - pharmacokinetics (18) 18
adolescent (17) 17
animals (17) 17
granulocyte colony-stimulating factor - economics (17) 17
medicine, general & internal (17) 17
original (17) 17
primary prophylaxis (17) 17
rehabilitation (17) 17
dose intensity (16) 16
hematology, oncology and palliative medicine (16) 16
macrophage colony stimulating factor (16) 16
neutrophils (16) 16
prophylaxis (16) 16
randomized-trial (16) 16
receiving myelosuppressive chemotherapy (16) 16
safety (16) 16
analysis (15) 15
granulocytes (15) 15
health aspects (15) 15
medicine, research & experimental (15) 15
oncology, experimental (15) 15
solid tumors (15) 15
time factors (15) 15
cancer patients (14) 14
colony-stimulating factors - therapeutic use (14) 14
cyclophosphamide (14) 14
double-blind method (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2018, Volume 84, Issue 12, pp. 2790 - 2801
Journal Article
Radiation Research, ISSN 0033-7587, 2015, Volume 183, Issue 6, pp. 643 - 655
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 2016, Volume 16, Issue 2, pp. 103 - 114.e3
Micro-Abstract In a phase III, double-blind trial, 845 patients with advanced colorectal cancer receiving bevacizumab plus first-line chemotherapy (FOLFOX... 
Hematology, Oncology and Palliative Medicine | Gastroenterology and Hepatology | Objective response rate | Chemotherapy | Overall survival | Progression-free survival | Febrile neutropenia | ADJUVANT CHEMOTHERAPY | MULTICENTER | COLONY-STIMULATING FACTOR | SINGLE-ADMINISTRATION PEGFILGRASTIM | FLUOROURACIL | BREAST-CANCER | ONCOLOGY | RELATIVE DOSE INTENSITY | CLINICAL-PRACTICE | DAILY FILGRASTIM | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Febrile Neutropenia - prevention & control | Incidence | Young Adult | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Double-Blind Method | Febrile Neutropenia - epidemiology | Proportional Hazards Models | Survival Rate | Filgrastim - administration & dosage | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - adverse effects | Prevention | Complications and side effects | Colorectal cancer | Drug therapy | Comparative analysis | Neutropenia | Cancer
Journal Article
BMC Cancer, ISSN 1471-2407, 01/2013, Volume 13, Issue 1, pp. 11 - 11
Journal Article
Pharmacology Research & Perspectives, ISSN 2052-1707, 10/2019, Volume 7, Issue 5, pp. e00507 - n/a
Journal Article
Pharmacology Research & Perspectives, ISSN 2052-1707, 10/2019, Volume 7, Issue 5, pp. e00503 - n/a
Journal Article
European Journal of Cancer Care, ISSN 0961-5423, 05/2009, Volume 18, Issue 3, pp. 280 - 286
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 06/2019, Volume 15, Issue 18, pp. 2083 - 2092
Pegfilgrastim is widely used for the prevention of chemotherapy-induced neutropenia. The development and use of biosimilar agents help to rationalize... 
ADULT PATIENTS | COST-EFFECTIVENESS | COLONY-STIMULATING FACTOR | EORTC GUIDELINES | SINGLE-ADMINISTRATION PEGFILGRASTIM | EUROPEAN-UNION | PRIMARY PROPHYLAXIS | neutropenia | INDUCED FEBRILE NEUTROPENIA | supportive therapy | BREAST-CANCER | pegfilgrastim | ONCOLOGY | cancer | pharmacoeconomics | biosimilar | DAILY FILGRASTIM
Journal Article